Icon
+91 94997 68112
Login Register

Minivelle - (0.025,0.0375,0.05,0.075,0.1mg/24HR;Film Extended)

ESTRADIOL Noven
0.025,0.0375,0.05,0.075,0.1mg/24HR;Film Extended
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
Less Than 5
 None
Indicated for treatment of moderate to severe vasomotor symptoms due to menopause.
Yes
*******, ***** **** ** ** *** ***** ** **** **** ** *** *.**** **/***, *.** **/***, *.*** **/***, *** *.* **/*** ****** ********* **** ******* ******* - *** **, **** *** ******* - *** *, **** *** **** ************ *********. ****** *** ****** ** ** ****** **** ********** *** ******* **** ***** ***** *** ***** ** ********** *** *** *****. * *** ******** ** ********* ***. *.*** **/*** *** ******* ** ********* *** *******(***), *****, ******* & ****** **** ********* *** *** *** ******** ***** **** *** ***** ********* **** ******* '***, '***, '*** *** ***** ******** ** **** **, ****. *** ********** ** ******* **** *** *** ********* ****** ***** & ******* *** *** *** ***** *********. **** ******* ** *****'* ********** *** *** *** ******** ***** ***** **** ***** **** *** ******** ******* ** ****. ***** ******** *** ******** ** ******* ******* *** ******** *** * *** ******* *****, ****** ***** **** ***** ****** *** ******, *** ********** *** ********* **** *****. ** ***** *** ** ***** **** ** *** ********** ** ******* ***** ** ****** *** *** ********* ***** ***** **** *.*. ***** ***** ****** ******. **** ******* ** ******* *********, ** ******* **** ** ******* *** *** ***** *** ***-************ ** **** ****** **** ***** *****. ***** ******* **** ******* ***** *** ***** ** ********** *** *** *****. *****, * ********* ** ******* ** ***** ** ****** *** ******* ***** ** ******* '*** *** '***. **** ****** **** *** **** ******* ***** ** ****** '***
Minivelle Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
******* ******* ******* ******* ******* *******
***** ******* ******* ******* ***** *** ** ** ******* ***** *** ** ** ******* ***** *** ** **
******* ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ ** **** **, **** ******* **** ****** **** ********
***** *** \ ** *** **, **** ******* ***** ***** *** ** ** ******** ******** ** *** *, ****
******* ** \ ** ***** **, **** ******* **** ****** **** ********
  1. *** *, **** : ******* ******** ***** ***** *** **** ** **** ******* ******* - *** **, **** *** ******* *** *, ****.
  2. *** **, **** : ***** ******** ***** ***** *** **** ** **** ******* ******* - *** **, **** *** ******* *** *, ****.
  3. *** **, **** : ***** ***** * **** ******* ******* ** ******** ***** ** ********.
  4. *** **, **** : ***** ***** * **** ******* *** ** ******** ***** ** ********.
  5. *** **, **** : ***** ***** * **** ******* ***** ** ***** ** ******** ***** ** ********.
  6. *** **, **** : ********** *** ******* **** ***** ***** *** ***** ** ********** *** *** *****.
  7. . : ***** *** ******** *** *** ******** ** ******** *.*. *.*** **/***.
  8. *** *, **** : ******* ******** ***** ***** *** **** ** *** *.*****/*** ******** **** ******* '***, '***, '*** *** ***** ******** ** **** **, ****.
  9. *** **, **** : ***** ***** * **** ******* ******* ** ******** ***** ** ********.
  10. **** **, **** : ******* ***** **** ** *** *.*** **/***, *.**** **/***, *.** **/***, *.*** **/***, *** *.* **/*** ****** ********* **** ******* '***, '***, '***
  11. *** **, **** : ***** ***** * **** ******* ******* ** ******** ***** ********.
  12. *** *, **** : ***** ***** * **** ******* ***** ** ***** ***** **** ** *** *.*****/*** ******** **** ******* '***, '***, '*** *** ***** ******** ** **** **, ****.
  13. *** *, **** : ***** ***** * **** ******* ****** ** ****** ***** **** ** *** *.*** **/***, *.**** **/***, *.** **/***, *.*** **/***, *** *.* **/*** ****** ********* **** ******* '***, '***, '*** *** ***** ******** ** **** **, ****.
  14. *** **, **** : ***** ***** * **** ******* ******* ** ******* ***** **** ** ****.*** **/***, *.**** **/***, *.** **/***, *.*** **/***, *** *.* **/*** ****** ********* **** ******* '***, '***, '*** *** ***** ******** ** **** **, ****.
  15. *** **, **** : ***** ***** * **** *********** *** ***** ****** ****** **** ****** '***.
  16. *** **, **** : ***** ***** **** ***** **** *** ******** *** ******* ** ****. ***** ******** *** ******** ** ******* *******.
  17. *** **, **** : ********** *** ********* **** ***** ***** *** ***** ** ********* *** *** *****.
  18. *** **, **** : ********** ********* **** ******* *** *.**** **/***, *.** **/***, *.*** **/*** ****** ********* *** ******* ******* - *** **, **** *** ******* - *** *, **** *.*. *** *** ******* ***** **********.
  19. *** **, **** : ***** *** ********. *****://***.**********.***.***/**********_****/*********/****/******************.***
  20. *** *, **** : ****** *** ********* ******** (****- ******)
  21. *** *, **** : ***** ******* **** ******* ***** *** ***** ** ********** *** *** *****.
  22. *** **, **** : * ********* ** ******* ** ***** ** ****** *** ******* ***** ** ******* '*** *** '***. **** ****** **** *** **** ******* ***** ** ****** '***

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.